MEVPRO-1 Deep Dive Preview: Framing the Upcoming Readout

Research evidence excerpt

MEVPRO-1 Deep Dive Preview: Framing the Upcoming Readout

Biotechnology Equity ResearchLarge Cap Pharmaceuticals

Financials

FY EPS

Rating Price 2026E 2026E 2027E 2027E FY Price Target Upside Downside

Company Name (Ticker) 06/09/26 Curr. Prior Curr. Prior 2026 2027 To From PT PT

Biotechnology

ORIC Pharmaceuticals, Inc. (ORIC) OW $8.00 $(1.30) NC $(1.39) NC $25.00 NC $35.00 $6.00

Large Cap Pharmaceuticals

Pfizer Inc. (PFE) EW $25.70 $2.98 NC $2.86 NC 8.6x 9.0x $28.00 NC $35.00 $20.00

Source: Company data and Wells Fargo Securities, LLC estimates, and Factset.

OW = Overweight, EW = Equal Weight, UW = Underweight, NR = Not Rated

NA = Not Available, NC = No Change, NE = No Estimate, NM = Not Meaningful

Key Questions We Look at in This Report

Exhibit 1 - Key Debates/Questions

Source: Wells Fargo Securities, LLC

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic castration-resistant prostate cancer (mCRPC) represents an advanced stage of prostate

cancer defined by disease progression despite sustained androgen suppression. Since prostate cancer

growth is largely driven by androgen receptor (AR) signaling, androgen deprivation therapy (ADT)—

via medical or surgical castration—is a foundational treatment and can control disease for prolonged

periods. However, resistance inevitably develops, leading to castration-resistant prostate cancer

(CRPC), characterized by tumor progression despite castrate testosterone levels (<50 ng/dL).

CRPC can present as either non-metastatic (nmCRPC) or metastatic (mCRPC), with the latter defined

by radiographic evidence of distant disease. mCRPC is associated with poor prognosis, limited duration

of response to available therapies, and accounts for the majority of prostate cancer-related mortality.